Literature DB >> 24591661

Interstitial lung disease.

Katerina M Antoniou1, George A Margaritopoulos, Sara Tomassetti, Francesco Bonella, Ulrich Costabel, Venerino Poletti.   

Abstract

Interstitial lung diseases are a group of diffuse parenchymal lung disorders associated with substantial morbidity and mortality. Knowledge achieved in recent years has resulted in the publication of the new classification of idiopathic interstitial pneumonias, according to which there are three groups: major, rare and unclassified. The novelty of the new classification comes from the fact that difficult to classify entities can be treated according to the disease behaviour classification. Idiopathic pulmonary fibrosis is the most lethal amongst the interstitial lung diseases and presents high heterogeneity in clinical behaviour. A number of biomarkers have been proposed in order to predict the course of the disease and group patients with the same characteristics in clinical trials. Early diagnosis and disease stratification is also important in the field of other interstitial lung diseases.

Entities:  

Mesh:

Year:  2014        PMID: 24591661     DOI: 10.1183/09059180.00009113

Source DB:  PubMed          Journal:  Eur Respir Rev        ISSN: 0905-9180


  48 in total

1.  Phenotypic Clusters Predict Outcomes in a Longitudinal Interstitial Lung Disease Cohort.

Authors:  Ayodeji Adegunsoye; Justin M Oldham; Jonathan H Chung; Steven M Montner; Cathryn Lee; Leah J Witt; Danielle Stahlbaum; Rene S Bermea; Lena W Chen; Scully Hsu; Aliya N Husain; Imre Noth; Rekha Vij; Mary E Strek; Matthew Churpek
Journal:  Chest       Date:  2017-09-28       Impact factor: 9.410

2.  Aberrant lung remodeling in a mouse model of surfactant dysregulation induced by modulation of the Abca3 gene.

Authors:  Michael F Beers; Lars Knudsen; Yaniv Tomer; Julian Maronn; Ming Zhao; Matthias Ochs; Surafel Mulugeta
Journal:  Ann Anat       Date:  2016-12-26       Impact factor: 2.698

3.  Pulmonary Toxicities of Immunotherapy.

Authors:  Mehmet Altan; Linda Zhong; Vickie R Shannon; Ajay Sheshadri
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

4.  Changes in Oxygenation and Serological Markers in Acute Exacerbation of Interstitial Lung Disease Treated with Polymyxin B Hemoperfusion.

Authors:  Song-I Lee; Chaeuk Chung; Dongil Park; Da Hyun Kang; Jeong Eun Lee
Journal:  J Clin Med       Date:  2022-04-28       Impact factor: 4.964

5.  The effectiveness of immunosuppressive cyclosporin in attenuating the progression of interstitial lung diseases.

Authors:  Mathew Suji Eapen; Archana Vijay Gaikwad; Isobel E Thompson; Wenying Lu; Stephen Myers; Pawan Sharma; Sukhwinder Singh Sohal
Journal:  J Thorac Dis       Date:  2019-05       Impact factor: 2.895

6.  Human antigen R promotes lung fibroblast differentiation to myofibroblasts and increases extracellular matrix production.

Authors:  Fatmah Al-Habeeb; Noof Aloufi; Hussein Traboulsi; Xingxing Liu; Parameswaran Nair; Christina Haston; Ilan Azuelos; Steven K Huang; Eric S White; Imed E Gallouzi; Sergio Di Marco; David H Eidelman; Carolyn J Baglole
Journal:  J Cell Physiol       Date:  2021-04-14       Impact factor: 6.513

Review 7.  Metabolic Disorders in Chronic Lung Diseases.

Authors:  Ourania Papaioannou; Theodoros Karampitsakos; Ilianna Barbayianni; Serafeim Chrysikos; Nikos Xylourgidis; Vasilis Tzilas; Demosthenes Bouros; Vasilis Aidinis; Argyrios Tzouvelekis
Journal:  Front Med (Lausanne)       Date:  2018-01-18

8.  A case of delayed exacerbation of interstitial lung disease after discontinuation of temsirolimus.

Authors:  Rei Matsuki; Kenichi Okuda; Akihisa Mitani; Yasuhiro Yamauchi; Goh Tanaka; Haruki Kume; Yukio Homma; Munetoshi Hinata; Akimasa Hayashi; Junji Shibahara; Masashi Fukayama; Takahide Nagase
Journal:  Respir Med Case Rep       Date:  2017-08-11

Review 9.  Venous Thromboembolic Disease in Chronic Inflammatory Lung Diseases: Knowns and Unknowns.

Authors:  George Keramidas; Konstantinos I Gourgoulianis; Ourania S Kotsiou
Journal:  J Clin Med       Date:  2021-05-11       Impact factor: 4.241

Review 10.  Stereotactic body radiation therapy (SBRT) in the management of non-small-cell lung cancer: Clinical impact and patient perspectives.

Authors:  Elysia K Donovan; Anand Swaminath
Journal:  Lung Cancer (Auckl)       Date:  2018-03-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.